Treating, chronic heart failure: Time to take stock

Lancet

Volumn 349, Issue 9057, 1997, Pages 966-967

  Niebauer, J ^a   Coats, A J S ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; IBOPAMINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEART FAILURE; HUMAN; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SURVIVAL; SYMPTOM; VASCULAR SMOOTH MUSCLE;

EID: 0030937697     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)22014-3     Document Type: Note

References (6)

1. CA Harvey DAA Owen Haemodynamic responses of ibopamine, an orally active dopamine analogue, in anaesthetised cats Br J Pharmacol 78 1983 127P (abstract).
2. M Metra L DeiCas Clinical efficacy of ibopamine in patients with chronic heart failure Clin Cardiol 18 suppl 1995 22 31
3. F Dies MJ Krell P Whitlow Intermittent dobutamine in ambulatory out patients with chronic cardiac failure Circulation 74 suppl. II 1986 138 (abstract).
4. M Packer J Carver RJ Rodenheffer Effect of oral milrinone on mortality in severe chronic heart failure N Engl J Med 325 1991 1468 1475
5. Mp Kullberg GB Freeman C Biddlecome Amrinone metabolism Clin Pharmacol Ther 29 1981 394 401
6. Otsuka America. Letter to VEST investigators, July 29, 1996.